Report Library
All Reports
Biomedtracker Early 2018 Outlook Report
February 01, 2018
In this report, we cover catalysts from 21 drugs expected to occur in Early 2018. For each drug, the likelihood of Phase/PDUFA review
success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of
the catalysts highlighted in our Q4 2017 Outlook Report can be found on Page 4. At the end
of this report, we have included a list of Large Impact catalysts through Early 2018.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.
Interested in medical devices? Our sister product Meddevicetracker has published a concurrent report on 9 device catalysts expected to occur in Early 2018. This report can be downloaded for free here.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.
Interested in medical devices? Our sister product Meddevicetracker has published a concurrent report on 9 device catalysts expected to occur in Early 2018. This report can be downloaded for free here.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: |
Alzheimer's Disease (AD)
Anesthesia Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)) Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL Cystic Fibrosis (CF) Exocrine Pancreatic Insufficiency HIV / AIDS Treatment Immune Thrombocytopenic Purpura (ITP) Major Depressive Disorder (MDD) Moderate to Severe Pain Neuroendocrine Tumors (NET) Pancreatic Cancer Prostate Cancer Psoriasis Spinal Muscular Atrophy Systemic Lupus Erythematosus (SLE) Uterine Fibroids Uveitis (Ophthalmology) X-Linked Hypophosphatemia (XLH) |
Additional Resources: